DRP Journal

Discover Research Profit

Finance 

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) Stock is All Set To gap-Up: How to Trade Now?

Pete Matthews , , , ,

NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) jumped 42% pre-market on no news. Recently the company released election results held during its annual shareholder meeting on July 9, 2021, in which Andrew I. Koven and Hyung Heon Kim were elected as NeuroBo Board of Directors.

 During the annual meeting, Jeong Gyun oh and Akash Bakshi didn’t stand for re-election. Kim said it is exciting to be part of the NeuroBo Board as it advancesits lead asset ANA001 into late-stage development for viral diseases. CEO Richard Kang welcomes Kim and Andrew, stating that their exceptional experience will be vital to advancing its multi-modal disease-changing viral therapies.

The company recently released its full-year 2020 financial results for the period ended December 31, 2021, and offered a corporate update. In addition, Kang said that in December, the company expanded its clinical pipeline with ANA Therapeutics’ acquisition and addition of ANA001, which is a novel oral niclosamide formulation in Phase 2/3 study for moderate to severe coronavirus treatment. So, in the coming months, NRBO is a stock to watch.

Market Reaction:

On Monday, NRBO stock jumped 3.30% at $2.82 with more than 4.49 million shares, compared to its average volume of 269k shares. The stock has moved within a range of $2.7000 – 2.9000 after opening the trade at $2.73. Over the past 52-week, the stock has been trading within a range of $2.7000 – 8.6500.

Pete Matthews

Pete attended the University of Colorado and still calls the centennial state home. He chases trout in the summer and snowboards in the winter. He is fascinated with the markets and has a strong interest in nanocap stocks and crypto currency.